urethra transitional cell carcinoma: Disease Detail

Profile Responses 0
Clinical Trials 110

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 0 to 0 of 0 entries

Molecular Profile	Therapy	Indication/Tumor Type	Response Type	Profile Response Detail
No data available in table

Showing 0 to 0 of 0 entries

Filter rows:

Showing 1 to 110 of 110 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT02496208	Phase I	Ipilimumab Cabozantinib + Nivolumab	Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors	Active, not recruiting	USA	0
NCT02516241	Phase III	Durvalumab + Tremelimumab Carboplatin + Cisplatin + Gemcitabine Durvalumab	Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer	Active, not recruiting	USA \| TUR \| POL \| NLD \| ITA \| ISR \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| BRA \| BEL \| AUT \| AUS	7
NCT02812420	Phase I	Durvalumab + Tremelimumab	Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy	Active, not recruiting	USA	0
NCT02989584	Phase Ib/II	Atezolizumab + Cisplatin + Gemcitabine	A Pilot Safety Study of Atezolizumab Combination With Cisplatin + Gemcitabine in Pts With Metastatic Bladder Cancer	Active, not recruiting	USA	0
NCT03093922	Phase II	Atezolizumab + Cisplatin + Gemcitabine	A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer	Active, not recruiting	USA	0
NCT03132922	Phase I	afamitresgene autoleucel	MAGE-A4c1032T for Multi-Tumor	Active, not recruiting	USA \| CAN	0
NCT03212404	Phase I	Cosibelimab	Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers	Active, not recruiting	POL \| NZL \| FRA \| ESP \| AUS	4
NCT03237780	Phase II	Atezolizumab Atezolizumab + Eribulin	Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer	Active, not recruiting	USA	0
NCT03459846	Phase II	Durvalumab + Olaparib Durvalumab	A Phase II Study of Durvalumab and Olaparib Compared to Durvalumab in Patients With Advanced, Cisplatin Ineligible Bladder Cancer. (BAYOU)	Active, not recruiting	USA \| ESP \| CAN	4
NCT03575013	Phase I	Avelumab + Docetaxel	A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer	Active, not recruiting	USA	0
NCT03682068	Phase III	Carboplatin + Durvalumab + Gemcitabine Carboplatin + Durvalumab + Gemcitabine + Tremelimumab Cisplatin + Durvalumab + Gemcitabine Cisplatin + Durvalumab + Gemcitabine + Tremelimumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine	Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE)	Active, not recruiting	USA \| TUR \| POL \| ITA \| ISR \| HUN \| ESP \| CZE \| CAN \| BRA \| BGR \| AUS \| ARG	9
NCT03821935	Phase I	ABBV-151 ABBV-151 + Budigalimab	Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors	Active, not recruiting	USA \| POL \| ITA \| ISR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS	4
NCT03869190	Phase Ib/II	Atezolizumab + Tocilizumab Atezolizumab + Niraparib Atezolizumab + Hu5F9-G4 Atezolizumab + Enfortumab vedotin-ejfv Atezolizumab + Linagliptin Atezolizumab + Isatuximab Atezolizumab	A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy (MORPHEUS mUC)	Active, not recruiting	USA \| GRC \| GBR \| FRA \| ESP	2
NCT04004442	Phase II	AVB-S6-500 + Avelumab	Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma (COAXIN)	Active, not recruiting	USA	0
NCT04152499	Phase Ib/II	SKB264	Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264)	Active, not recruiting	USA \| TUR \| CAN	3
NCT04637594	Phase III	Durvalumab Nivolumab Atezolizumab Avelumab Pembrolizumab	Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy	Active, not recruiting	USA	0
NCT04940299	Phase II	Ipilimumab + Nivolumab + Tocilizumab	Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma	Active, not recruiting	USA	0
NCT04953104	Phase II	Nivolumab and relatlimab-rmbw	ARID1A and/or KDM6A Mutation and CXCL13 Expression	Active, not recruiting	USA	0
NCT05077709	Phase II	IO102-IO103 + Pembrolizumab	IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC	Active, not recruiting	USA \| GBR \| ESP	0
NCT05092958	Phase III	Avelumab + Cabozantinib Avelumab	Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study	Active, not recruiting	USA \| CAN	0
NCT05176483	Phase I	Nivolumab + NKTR-214 XL092 Nivolumab + NKTR-214 + XL092 Ipilimumab + Nivolumab + XL092 Nivolumab + XL092 Ipilimumab + Nivolumab	Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002)	Active, not recruiting	USA \| POL \| NZL \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CHE \| BEL \| AUT \| AUS	0
NCT05562830	Phase Ib/II	VLS-101 MK-3120 + Pembrolizumab	A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)	Active, not recruiting	USA \| ISR \| ESP \| DNK \| AUS	2
NCT02589717	FDA approved	Atezolizumab	An Expanded Access Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy	Approved for marketing	USA	0
NCT00942331	Phase III	Bevacizumab + Cisplatin + Gemcitabine Cisplatin + Gemcitabine	Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer	Completed	USA	1
NCT01108055	Phase II	Paclitaxel + Pazopanib	Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer	Completed	USA	0
NCT01326871	Phase Ib/II	ALT-801	A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer	Completed	USA	0
NCT01780545	Phase II	Apatorsen Docetaxel	Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer	Completed	USA	0
NCT02014337	Phase I	Eribulin + Mifepristone	Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors	Completed	USA	0
NCT02091999	Phase I	Enfortumab vedotin-ejfv	A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4	Completed	USA \| CAN	0
NCT02108652	Phase II	Atezolizumab	A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer	Completed	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN	0
NCT02178722	Phase Ib/II	Epacadostat + Pembrolizumab	Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers	Completed	USA	0
NCT02236195	Phase II	Mocetinostat	Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes	Completed	USA	0
NCT02240238	Phase Ib/II	Gemcitabine + NC-6004	Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer	Completed	USA \| ROU \| POL \| ITA \| BGR	0
NCT02256436	Phase III	Pembrolizumab	A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)	Completed		0
NCT02300610	Phase I	Cisplatin + Gemcitabine Enzalutamide	Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer	Completed	USA	0
NCT02302807	Phase III	Paclitaxel Vinorelbine Atezolizumab Docetaxel	A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer	Completed	USA \| TUR \| SWE \| SVN \| ROU \| POL \| NOR \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BEL \| AUT \| AUS	6
NCT02335424	Phase II	Pembrolizumab	Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)	Completed		0
NCT02365766	Phase Ib/II	Cisplatin Pembrolizumab Gemcitabine	Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer	Completed	USA	0
NCT02365818	Phase II	CG0070	Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure	Completed	USA	0
NCT02387996	Phase II	Nivolumab	A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer	Completed	USA \| SWE \| POL \| ITA \| FIN \| ESP \| DEU \| CZE \| BEL \| AUS	1
NCT02426125	Phase III	Ramucirumab Docetaxel	A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer	Completed	USA \| TUR \| ROU \| POL \| NLD \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| BEL \| AUS	6
NCT02437370	Phase I	Pembrolizumab Gemcitabine Docetaxel	Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer	Completed	USA	0
NCT02459119	Phase II	Regorafenib	Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)	Completed	USA	0
NCT02500121	Phase II	Pembrolizumab	Testing the PD-1 Inhibitor Pembrolizumab After Initial Chemotherapy in Patients With Metastatic Bladder Cancer	Completed	USA	0
NCT02553642	Phase II	Nivolumab Ipilimumab	Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)	Completed	USA	0
NCT02567409	Phase II	Cisplatin + Gemcitabine Berzosertib + Cisplatin + Gemcitabine	Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer	Completed	USA	0
NCT02581982	Phase II	Pembrolizumab Paclitaxel	Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer	Completed	USA	0
NCT02619253	Phase Ib/II	Pembrolizumab + Vorinostat	Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma	Completed	USA	0
NCT02646748	Phase I	Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab	Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors	Completed	USA	0
NCT02788201	Phase II	Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane	Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma	Completed	USA	0
NCT02807636	Phase III	Atezolizumab + Carboplatin + Gemcitabine Carboplatin + Gemcitabine	The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy	Completed	USA \| TUR \| SVN \| ROU \| POL \| NLD \| ITA \| ISR \| GRC \| GBR \| FIN \| EST \| ESP \| CZE \| CAN \| BRA \| BEL \| AUS	17
NCT02853305	Phase III	Pembrolizumab Carboplatin + Cisplatin + Gemcitabine	Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)	Completed		0
NCT02897765	Phase I	Nivolumab NEO-PV-01 + Poly ICLC	A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer	Completed	USA	0
NCT02989064	Phase I		MAGE-A10c796T for Urothelial Cancer, Melanoma or Head and Neck Cancers	Completed	USA \| ESP \| CAN	0
NCT03359239	Phase I	Atezolizumab + PGV 001	Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer	Completed	USA	0
NCT03361865	Phase III	Epacadostat + Pembrolizumab Pembrolizumab	Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)	Completed	USA \| POL \| NLD \| ITA \| ISR \| IRL \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS	5
NCT03374488	Phase III	Epacadostat + Pembrolizumab Pembrolizumab	Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma	Completed	USA \| TUR \| NLD \| ITA \| ISR \| IRL \| HUN \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| AUS	4
NCT03410693	Phase II	Docetaxel Vinflunine Paclitaxel Rogaratinib	Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma (FORT-1)	Completed	USA \| SWE \| SVK \| POL \| NLD \| ITA \| ISR \| IRL \| HUN \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BEL \| AUT \| AUS	8
NCT03425201	Phase Ib/II	Cabozantinib + Niraparib	Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA) (NICARAGUA)	Completed	ESP	0
NCT03451331	Phase II	Carboplatin + Gemcitabine + Nivolumab Gemcitabine + Nivolumab + Oxaliplatin	Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer	Completed	USA	0
NCT03472274	Phase II	Cisplatin + Doxorubicin + Methotrexate + Vinblastine Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Paclitaxel Durvalumab + Tremelimumab	Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO) (DUTRENEO)	Completed	ESP	0
NCT03473756	Phase Ib/II	Atezolizumab Atezolizumab + Rogaratinib	Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2)	Completed	USA \| ITA \| FRA \| ESP \| DEU \| AUT	2
NCT03502785	Phase Ib/II	Atezolizumab + INO-5401 + Rocakinogene sifuplasmid	INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma	Completed	USA	0
NCT03513952	Phase II	Atezolizumab + CYT107 Atezolizumab	Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma	Completed	USA	0
NCT03517956	Phase I	Copanlisib + Rogaratinib	Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors (ROCOCO)	Completed	USA \| ESP \| DEU \| BEL	2
NCT03557918	Phase II	Tremelimumab	Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer	Completed	USA	0
NCT03628716	Phase II	Atezolizumab + CV301	CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer	Completed	USA	0
NCT03898180	Phase III	Lenvatinib + Pembrolizumab Pembrolizumab	Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)	Completed	USA \| TUR \| POL \| NLD \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| AUS \| ARG	5
NCT03980041	Phase II	Nivolumab Eganelisib + Nivolumab	Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)	Completed	USA \| POL \| ITA \| FRA \| ESP \| CZE	1
NCT04602078	Phase II	Atezolizumab + Cisplatin + Gemcitabine	Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma (AUREA)	Completed	ESP	0
NCT04925284	Phase I	XB002 Nivolumab + XB002	Study of XB002 in Subjects With Solid Tumors (JEWEL-101)	Completed	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| BEL \| AUS	1
NCT04724018	Phase I	Enfortumab vedotin-ejfv + Sacituzumab govitecan-hziy	Sacituzumab Govitecan Plus EV in Metastatic UC	Enrolling by invitation	USA	0
NCT01174121	Phase II	Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin	Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer	Recruiting	USA	0
NCT04143711	Phase Ib/II	DF1001 DF1001 + Pembrolizumab	Study of DF1001 in Patients with Advanced Solid Tumors	Recruiting	USA \| NLD \| FRA \| DNK \| BEL	1
NCT04678362	Phase II	Avelumab + Talazoparib	TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma (TALASUR)	Recruiting	FRA	0
NCT04701918	Phase II	Pembrolizumab	Pembrolizumab And Cryoablation In Urothelial Carcinoma	Recruiting	USA	0
NCT04848519	Phase II	Pembrolizumab + Propranolol	Propranolol Hydrochloride and Pembrolizumab for the Treatment of Recurrent or Metastatic Urothelial Cancer	Recruiting	USA	0
NCT04879329	Phase II	Disitamab vedotin Disitamab vedotin + Pembrolizumab	A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2	Recruiting	USA \| ITA \| ISR \| GBR \| ESP \| CAN \| BEL \| AUS \| ARG	2
NCT04963153	Phase I	Enfortumab vedotin-ejfv + Erdafitinib	Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy	Recruiting	USA \| CAN	0
NCT05219435	Phase II	Ipilimumab + Nivolumab	Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer (VEXILLUM)	Recruiting	ESP	0
NCT05239624	Phase II	Enfortumab vedotin-ejfv + Pembrolizumab	Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer	Recruiting	USA	0
NCT05911295	Phase III	Disitamab vedotin + Pembrolizumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine	Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2	Recruiting	USA \| SWE \| NOR \| NLD \| ITA \| ISR \| IRL \| HUN \| GRC \| GBR \| FRA \| ESP \| CZE \| CAN \| BRA \| BEL \| AUS \| ARG	7
NCT06172478	Phase II	Patritumab deruxtecan	A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors	Recruiting	USA \| GBR \| FRA \| ESP \| CAN \| BEL \| AUS	3
NCT06225596	Phase II	Avelumab + Carboplatin + Gemcitabine Avelumab + Cisplatin + Gemcitabine BT8009 BT8009 + Pembrolizumab	Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)	Recruiting	USA \| TUR \| POL \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	6
NCT06632951	Phase II	ABBV-151 + Budigalimab Gemcitabine Docetaxel Paclitaxel	Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) (LIVIGNO-3)	Recruiting	USA \| POL \| ISR \| FRA \| ESP \| CAN	2
NCT06660654	Phase II	Raludotatug deruxtecan	A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)	Recruiting	USA \| ITA	1
NCT06892860	Phase II	Avelumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine	Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer (DISCUS)	Recruiting	GBR \| FRA \| ESP	0
NCT01215136	Phase II	Everolimus Paclitaxel	First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma	Terminated	USA	0
NCT02122172	Phase II	Afatinib	Afatinib in Advanced Refractory Urothelial Cancer	Terminated	USA	0
NCT02334527	Phase II	Palbociclib	Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy	Terminated	USA	0
NCT02401542	Phase Ib/II	Docetaxel + Vofatamab Vofatamab Docetaxel	Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (FIERCE-21)	Terminated	USA \| TUR \| SWE \| ITA \| GBR \| ESP \| CZE	2
NCT02479178	Phase II	BIND-014	A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2)	Terminated	USA	1
NCT02559492	Phase I	Epacadostat + Itacitinib Itacitinib + Parsaclisib	INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors	Terminated	USA	0
NCT02612194	Phase II	Crizotinib	LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer	Terminated	USA	0
NCT02925533	Phase I	Pembrolizumab + Vofatamab	Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract	Terminated	USA	0
NCT03272217	Phase II	Atezolizumab + Bevacizumab	Atezolizumab With or Without Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer	Terminated	USA	0
NCT03317496	Phase II	Avelumab + Cisplatin + Gemcitabine Avelumab + Carboplatin + Pemetrexed Disodium	Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies	Terminated	USA \| ITA \| HUN \| GBR \| ESP \| CZE \| CAN \| AUS	0
NCT03397394	Phase II	Rucaparib	Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (ATLAS)	Terminated	USA \| ITA \| GBR \| FRA \| ESP \| DEU	0
NCT03666988	Phase I	GSK3368715	First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)	Terminated	USA \| ESP \| CAN \| AUS	0
NCT03737123	Phase II	Atezolizumab + Carboplatin + Gemcitabine	Trial of Atezolizumab Plus Chemotherapy After Progression on Single Agent PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma	Terminated	USA	0
NCT03915405	Phase I	Avelumab + KHK2455	KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer	Terminated	USA \| ESP	0
NCT04349280	Phase I	Bintrafusp alfa	A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer	Terminated	USA \| NLD \| FRA \| ESP \| CAN	0
NCT04501094	Phase II	Bintrafusp alfa	A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma	Terminated	USA	0
NCT06630247	Phase I	XL495	A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors	Terminated	USA	0
NCT03170960	Phase Ib/II	Atezolizumab + Cabozantinib	Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	Unknown status	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL \| AUS	0
NCT03824691	Phase II	Cabozantinib + Durvalumab	hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study" (ARCADIA)	Unknown status	ITA	0
NCT03935347	Phase II	Aldesleukin + Cyclophosphamide + Fludarabine + LN-145 + Pembrolizumab	Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy	Withdrawn	USA	0
NCT04064190	Phase II	Durvalumab + Vactosertib	Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition	Withdrawn	USA	0
NCT04179110	Phase II	Pembrolizumab + Ramucirumab	Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor	Withdrawn	USA	0
NCT05894447	Phase I	Naptumomab estafenatox + Pembrolizumab Obinutuzumab	Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers	Withdrawn	USA	0

Showing 1 to 110 of 110 entries

Filter rows:

ID	DOID:4013
Name	urethra transitional cell carcinoma
Definition	An urethra cancer that is characterized by cancer cells forming in the renal pelvis and ureter.
Source	DiseaseOntology.org
Alt Ids
Path	disease disease of cellular proliferation cancer organ system cancer urinary system cancer urethra cancer urethra transitional cell carcinoma

urethra transitional cell carcinoma
Disease Detail

Contact

Filtering

Sorting

urethra transitional cell carcinomaDisease Detail

Contact

Filtering

Sorting

urethra transitional cell carcinoma
Disease Detail